The article focuses on a study presented by physician Ursula M. Schmidt-Erfurth which found that regression in drusen volume which can be measured by spectral-domain optical coherence tomography is a prognostic indicator of whether advanced-stage disease, like choroidal neovascularization (CNV) and geographic atrophy will progress.